Libtayo® (cemiplimab for injection) Now Reimbursed in Seven Provinces for Advanced Non-Small Cell Lung Cancer and Locally Advanced Basal Cell Carcinoma

Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, British Columbia, Saskatchewan, Nova Scotia, Newfoundland and ...

Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer

Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du Québec (RAMQ) in Québec for adults with advanced non-small cell ...
TipRanks on MSN

Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a significant clinical ...
TipRanks on MSN

Akeso, Inc. Launches Promising Phase III Study for Lung Cancer Treatment

Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. has announced a new clinical study titled ‘A ...